# US 2001/0041183 A1 · Vaccines against varicella zoster virus gene 63 product

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2001/0041183 A1
- Document ID: US20010041183A1
- Status: Published application
- Kind: A1
- Application number: 09/865,637
- Filed: 2001-05-25
- Published: 2001-11-15
- Earliest claimed: 1996-02-09
- Assignees: SmithKline Beecham Biologicals s.a.
- Inventors: Bernard Rentier; Catherine Sadzot
- Web page: https://patentgrep.com/patent/US20010041183A1

## CPC

- C07K 14/005: from viruses
- A61K 39/12: Viral antigens
- A61K 39/25: Varicella-zoster virus
- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- C12N 2710/16722: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2710/16734: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention relates to compositions for the treatment or prevention of Zoster of individuals infected with Varicella Zoster virus (VZV), and to the prevention and treatment of Varicella infections. The compositions of the invention comprise the protein encoded by VZV gene 63 or an immunologically active derivative thereof. The invention further relates to compositions containing DNA or RNA corresponding to VZV gene 63.

## Claims

### Claim 1

A pharmaceutical composition comprising Varicella Zoster Virus IE63 protein or an immunologically functional derivative and a pharmaceutically acceptable excipient.

### Claim 2

A pharmaceutical composition comprising a nucleic acid encoding IE63 or an immunologically functional derivative thereof.

### Claim 3

IE63 gene protein or immunologically functional derivative thereof for use in medicine.

### Claim 4

Use of IE63 protein or an immunologically active derivative thereof for the manufacture of a medicament for the prevention or amelioration of Varicella or Zoster.

### Claim 5 (depends on 1)

A pharmaceutical composition as claimed in claim 1 additionally comprising other VZV antigens.

### Claim 6 (depends on 5)

A pharmaceutical composition as claimed in claim 5 wherein the second Varicella Zoster protein is selected from the group, gpI, gpII, gpIII, gpIV, gpV or IE62 or immunological functional derivative thereof.

### Claim 7 (depends on 1, 2, 5, 6)

A pharmaceutical composition as claimed in claim 1, 2, 5 or 6 additionally comprising an adjuvant.

### Claim 8 (depends on 7)

A pharmaceutical composition as claimed in claim 7 wherein the adjuvant preferentially induces a TH1 response.

### Claim 9 (depends on 9)

A pharmaceutical composition as claimed in claim 9 wherein the antigen is presented as an oil in water emulsion together with QS21 and 3D-MPL.

### Claim 10 (depends on 1, 2, 5, 6, 7, 8, 9)

A method of treating a patient suffering from or susceptible to Varicella Zoster virus infection, comprising administering to a patient a safe and effective amount of a pharmaceutical composition as claimed in any one of claims 1, 2, 5, 6, 7, 8 or 9.

### Claim 11

A method of producing a pharmaceutical composition comprising a Varicella Zoster virus IE63 protein, nucleic acid or immunologically functional derivative thereof, comprising mixing said protein, nucleic acid or derivative with a pharmaceutically acceptable excipient.

### Claim 12 (depends on 11)

A method as claimed in claim 11, wherein the excipient comprises an adjuvant.
